CCR2: Characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach

Theo Berkhout, F.E. Blaney, A.M. Bridges, D.G. Cooper, I.T. Forbes, A.D. Gribble, P.H.E. Groot, A. Hardy, R.J. Ife, R. Kaur, K.E. Moores, H. Shillito, J. Willetts, J. Witherington

Research output: Contribution to journalArticlepeer-review

87 Citations (Scopus)

Abstract

We describe here a classical molecular modeling exercise that was carried out to provide a basis for the design of novel antagonist ligands of the CCR2 receptor. Using a theoretical model of the CCR2 receptor, docking studies were carried out to define plausible binding modes for the various known antagonist ligands, including our own series of indole piperidine compounds. On the basis of these results, a number of site-directed mutations (SDM) were designed that were intended to verify the proposed docking models. From these it was clear that further refinements would be necessary in the model. This was aided by the publication of a crystal structure of bovine enabled us to define ligand-docking hypotheses that were in complete agreement with the results of the SDM experiments.

Original languageEnglish
Pages (from-to)4070-4086
Number of pages17
JournalJournal of Medicinal Chemistry
Volume46
Issue number19
DOIs
Publication statusPublished - 11 Sept 2003

Keywords

  • DEFICIENT MICE
  • MONOCYTE CHEMOATTRACTANT PROTEIN-1
  • SMALL-MOLECULE
  • AGENTS
  • IN-VITRO
  • ATHEROSCLEROTIC LESIONS
  • POTENT
  • IDENTIFICATION
  • CHEMOKINE RECEPTORS
  • COUPLED RECEPTORS

Fingerprint

Dive into the research topics of 'CCR2: Characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach'. Together they form a unique fingerprint.

Cite this